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Introduction: Whereas salivary gland pleomorphic adenoma (SGPA) is the most common type of salivary
gland tumor, little is known about its epidemiology because national cancer registries do not register this
disease.
Objectives: To establish SGPA incidence trends, rates of secondary malignant transformation and recur-
rence and associated factors in the Netherlands.
Materials and methods: Data on incidence, epidemiology, secondary malignant transformation and recur-
rence were retrieved from the Dutch pathology registry (PALGA) for the years 1992, 1997, 2002, 2007,
and 2012. Multivariate analysis was performed to discover the risk factors for recurrence.
Results: 3506 cases of SGPA were recorded implying an overall European standardized rate of 4.2–4.9 per
100,000 person-years. Our figures showed a female preponderance (1:1.43) with an annual 1% rise in
female incidence (95% confidence interval [CI]: 0.2–1.8) and a bimodal age distribution in women
(p < 0.0001). The overall 20-year recurrence rate was 6.7%, and median time to first recurrence was
7 years.
Positive and uncertain resection margins and younger age at diagnosis were risk factors for recurrence,
with odds ratios (ORs) of 4.62 (95%CI 2.84–7.51), 4.08 (95%CI 2.24–7.43), and 0.42 (95%CI 0.29–0.63)
respectively. Tumor locations in the minor salivary glands had lower odds of recurrence than tumors
in the parotid (OR 0.24; 95% CI: 0.07–0.77; p < 0.016). Malignant transformation occurred in 0.15% of
SGPAs (3.2% of recurrences).
Conclusion: This first nationwide study clearly showed sex differences in SGPA epidemiology, possibly
suggesting some underlying hormonal mechanism. Long-term recurrence risks were low, and secondary
malignant transformation risks were very low.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Most salivary gland tumors are benign, with malignancy found
in roughly 14% of lesions [1,2]. The most common tumor type is
salivary gland pleomorphic adenoma (SGPA), which accounts for
more than 70% of benign epithelial tumors. These well-
circumscribed tumors with ductal and myoepithelial elements
are found in both the major and minor salivary glands with most
94 M.H. Valstar et al. / Oral Oncology 66 (2017) 93–99occurring in the parotid gland. They are more common in women
and age at diagnosis is mostly between 40 and 59 years old [2,3].
The standard of treatment is nerve-conserving, superficial
parotidectomy (or extracapsular dissection in well trained hands).
Recurrence is reported in 0–3% of patients [4,5]. Historically, enu-
cleation was performed but this was associated with unacceptably
high recurrence rates of up to 45% [6,7]. Results of postoperative
radiotherapy for recurrent SGPA, show better local control (up to
94% after 20 years follow-up) than surgery only, in retrospective
series [6,8,9].
In 1.8–6.2% of cases, SGPA transforms into carcinoma ex pleo-
morphic adenoma [4,10]. These cases make up 7.7–11.6% of all
malignant salivary gland tumors [10,11]. In recurrent SGPA, de
novo malignant transformation is reported in 0–23% [6].
As common a tumor as SGPA may be, its epidemiology has long
remained uncertain for lack of national registration [4,12,13]. The
literature reports research focused on benign salivary gland tumors
in general or subgroups of SGPA [2,14–17]. Others have looked at
regional incidence of SGPA or national incidence of parotid SGPA
[1,4], but to our knowledge, national incidence of all-location SGPA
and trends over time have not been investigated.
Of course, without any national data, no rates can be calculated
for all-location SGPA incidence, recurrence, and secondary malig-
nant transformation without a strong possibility of referral bias.
We, therefore, decided to use the Dutch nationwide registry of
pathology reports (PALGA). This registry is not restricted to any
specific type of finding or disease, thus making a suitable database
for studying SGPA epidemiology features, including trends over
time.
Objectives
Our primary aim was to accurately establish SGPA incidence
rates and trends over time, as well as any age and sex differences.
We further aimed to establish recurrence rates and risks of sec-
ondary malignant transformation and to explore risk factors. This
knowledge will help physicians to measure treatment results and
express population-based prognoses.
Materials and methods
Database
Set up in 1991, the PALGA registry automatically receives anon-
ymized pathology reports from all Dutch laboratories, which
include age, sex, date, and diagnosis. Excerpts are available for
research purposes.
Patient selection
We searched the PALGA registry for codes of pleomorphic ade-
noma or mixed tumor and manually checked all excerpts thus cre-
ated for SGPA. Then, we included all patients who had a first
histology diagnosis in 1992, 1997, 2002, 2007, or 2012. We
excluded 442 patients (11%) for reasons mentioned in Additional
Table A. Likewise, we analyzed histology and cytology data for
recurrences up to September 1, 2013, defining recurrence as a sec-
ondary tumor occurring in the same tumor site at a minimum of
six months post surgery.
Incidence
We calculated SGPA incidence in the Netherlands from mid-
year population size figures provided by Statistics Netherlands
(CBS) [18], and worked out the male to female incidence ratio bylooking at average male and female incidence data. To cancel out
changes in age structure of the Dutch population over time, we
computed European standardized incidence rates (ESRs), basing
our calculations on the ‘‘2013 reference population” [19,20].
Patient, tumor, and treatment characteristics
To further analyze our primary tumor data, we recorded sex,
age at diagnosis, salivary gland of origin, side of the body, surgical
procedure, and margin status. In case of ambiguity, we checked
with the author pathologist to decide on interpretation.
Recurrence rates and malignant transformation
In the subgroup of patients with at least five years of follow-up,
we calculated first-recurrence rates at 5, 10, and 15 years, as well
as median time to first and subsequent recurrences. We excluded
primary carcinomas ex pleomorphic adenoma from our database,
and counted secondary carcinomas ex pleomorphic adenoma
(SGPAs that recurred as malignant tumors) both as malignant
transformations and as recurrences. Carcinomas in situ ex pleo-
morphic adenoma were not considered malignant transformations.
Risk factors for recurrence
We investigated sex, age, tumor site, and margin status. As the
type of surgery was not always specified, and reporting practices
varied, we decided to exclude this factor for our study.
Statistical analysis
We analyzed our data with SPSS (version 21.0; SPSS Inc., Chi-
cago, III) and R [21,22], taking a p-value of <0.05 to be statistically
significant for all purposes. Using linear regression and the natural
log rhythm of ESR, we computed annual percent changes (APCs) by
sex and overall, and we applied finite mixture models to investi-
gate distribution patterns for age at diagnosis [23]. With the
Kaplan-Meier method, we calculated times to recurrence and iden-
tified potential predictors for recurrence using multivariate logistic
regression analysis. In addition to our analysis of complete cases,
we performedmissing data analysis and multiple-imputation anal-
ysis, imputing missing data by letting the R MICE package generate
five imputed datasets and comparing the pooled results to our
analysis of complete cases.
Results
Incidence
After data cleaning, 3504 unique patients remained of a total of
3948 diagnosed with pleomorphic adenoma (Table 1). Two
patients developed a second primary SGPA at a different anatomi-
cal site. Overall crude incidence varied from 3.9 to 4.7 per 100,000
person-years (Tables 2a and 2b). ESR ranged between 4.2 and 4.9
per 100,000 person-years. After stratifying for sex, we found a sta-
tistically significant annual rise of ESR in women (APC = 1.0% per
year; 95% CI: 0.2–1.8), but not in men (APC = 0% per year; 95% CI:
1.0 to 0.9) (Fig. 1).
Patient, tumor, and treatment characteristics
Primary SGPAs occurred more often in women (59.5%) than in
men (40.5%) (Table 1), showing a female to male ratio of 1.43:1.
The mean age at primary diagnosis was 48.0 in men, and 49.6 in
women. Seventy-eight patients (2%) were under 18 when
Table 1
Population characteristics primary SGPA and 1st recurrence.
Primary (%) 1st Recurrence (%)
Overall (n = 3506) Male (n = 1421) Female (n = 2085) Overall (n = 125)
Patients
Age Mean (range) 49 (8–94) 48 (9–92) 50 (8–94) 39 (8–89)
Age group 0–19 112 (3) 54 (4) 58 (3) 12 (10)
20–39 959 (27) 393 (28) 566 (27) 60 (48)
40–59 1417 (40) 600 (42) 817 (39) 33 (26)
60–79 919 (26) 343 (24) 576 (28) 18 (14)
P80 99 (3) 31 (2) 68 (3) 2 (2)
Location Parotid gland 2733 (78) 1112 (78) 1621 (78) 110 (88)
Superficial lobe 2603 (74) 1066 (75) 1537 (74) 102 (82)
Deep lobe 130 (4) 46 (3) 84 (4) 8 (6)
Submandibular gland 310 (9) 93 (7) 217 (10) 9 (7)
Sublingual gland 6 (<1) 4 (<1) 2 (<1) 0
Minor salivary glands 377 (11) 187 (13) 190 (9) 6 (5)
Unknown 38 (1) 13 (<1) 25 (1) 6 (5)
Missing 42 (1) 12 (<1) 30 (1) 0
Side Left 1423 (41) 571 (40) 852 (41) 64 (51)
Right 1399 (40) 560 (39) 839 (40) 53 (42)
Unknown 684 (19) 290 (20) 394 (19) 8 (6)
Treatment
Procedure Local excision 297 (8)
Partial parotidectomy 1214 (35)
Total parotidectomy/submandib. gl.resection 227 (6)
Subtotal parotidectomy 67 (2)
Excision deep lobe parotid 103 (3)
Biopsy 114 (3)
Unknown type of excision 1449 (41)
Missing 35 (1)
Clear margins Negative 2028 (58)
Positive 491 (14)
Uncertain 261 (7)
Unknown 726 (21)
Table 2a
Number of SGPAs in the cohort in relation to the Dutch population.
SGPAs (n) Dutch population (n)
M F Total M F Total
1992 253 343 596 7,480,422 7,648,728 15,129,150
1997 280 384 664 7,696,803 7,870,304 15,567,107
2002 288 401 689 7,971,967 8,133,318 16,105,285
2007 304 466 770 8,088,514 8,269,478 16,357,992
2012 296 491 787 8,282,871 8,447,477 16,730,348
Total 1421 2085 3506
Abbreviations: SGPA salivary gland pleomorphic adenoma; M male; F female.
Table 2b
Incidence of SGPAs in the Dutch population.
Crude incidence (per 100,000 per year) ESR (per 100,000 per year)
M F Total M F Total
1992 3.38 4.48 3.94 3.60 4.78 4.19
1997 3.64 4.88 4.27 3.91 5.11 4.54
2002 3.61 4.93 4.28 3.78 5.02 4.39
2007 3.76 5.64 4.71 3.88 5.79 4.85
2012 3.57 5.81 4.70 3.57 5.81 4.69
Abbreviations: ESR European Standardized Rate; SGPA Salivary Gland Pleomorphic Adenoma; M Male; F Female.
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59. In women, a bimodal age distribution was found, with peaks
around the ages of 38 and 64 (p < 0.0001). Age in men showed a
normal distribution (Fig. 2).
The most common tumor site by far was the parotid gland
(78%), followed by the minor salivary glands (11%) and thesubmandibular glands (9%). Only six SGPAs occurred in sublingual
glands (<1%).
Submandibular SGPAwasmore common inwomen than inmen,
but minor-gland SGPA was more common in men than women
(Table 1). In patients under 18, the minor and submandibular
glands were affected more often than in adults (Additional Table B).
Fig. 1. European Standardized Rate (ESR) in the five investigated years, with
interpolation in the periods in between. The annual percent change (APC),
calculated from the five years, shows an increase in female SGPA incidence.
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local excision (8%) and complete gland removal (6%). In 41% of
cases the excerpts did not specify the surgical technique and in
1%, there was no mention of type of procedure at all. Histological
margins were negative in 58%, positive in 14%, uncertain in 7%,
and not reported in 21%.Recurrence rates, characteristics, and malignant transformation
The disease recurred in 125 (4.6%) of the 2719 patients who had
at least five years of follow-up. Twenty (16%) also had a second
recurrence, and two (10%) had a third. In 4 patients (0.15%), the
disease recurred as carcinoma ex pleomorphic adenoma, whichFig. 2. Age distribution, showingmeans that 3.2% of all recurrences (4/125) showed malignant
transformation. First-recurrence rates were 2.3% at five years,
4.0% at 10 years, 5.6% at 15 years, and 6.7% at 20 years of follow-
up, with a 7 years’ median time to first recurrence (range 0.6–
20.7, 95% CI 5.9–8.1) (Fig. 3). Second-recurrence rates were 12%
at five years and 14% at ten years of follow-up. The median time
to second recurrence was 2 years (95% CI: 0.9–3.1). Sex distribution
patterns were similar in both recurrences and primary tumors
(58% females versus 42% males). The mean age at primary diagno-
sis was 40 in patients who later developed recurrent disease and
49.3 in patients who did not develop recurrent disease. This 10-
year age difference appeared in both sexes.Risk factors for recurrence
Margin status, age at diagnosis, and tumor location were all
associated with risk of recurrence (Table 3). In patients with a
reported margin status (complete cases, n = 1663), positive resec-
tion margins had an odds ratio for recurrence of 4.62 (95% CI
2.84–7.51), and 4.08 for uncertain margins (95% CI 2.24–7.43)
compared to clear margins. For young age at diagnosis, the odds
ratio was 0.42% (per IQR [25y]; 95% CI 0.29–0.63). Primary tumor
location showed an odds ratio of 0.24 for minor salivary gland dis-
ease when compared to parotid disease (95% CI 0.07–0.77). Risk
factors for malignant transformation of recurrent SGPA could not
be determined, due to the low event rate (0.15%).Missing data and imputation
Type of surgery performed and margin status were not men-
tioned in 42% and 21% of excerpts, respectively. There were 1663
patients with complete information. Missing data on resection
margins showed a significant association with recurrence (OR
1.5; 95% CI 1.00–2.23; p = 0.04). Taking this association into
account, our analysis of imputed data with multiple-imputationa bimodal curve in women.
Fig. 3. Recurrence-free survival in patients who develop a recurrence, reflecting a
decrease in median time to recurrence: 7 years to 1 s recurrence and 2 years
between 1st and 2nd.
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data (Table 3).Discussion
We report a large cohort of 3506 patients with extended peri-
ods of follow-up and investigated SGPA incidence, recurrence,
and secondary malignant transformation. Novel findings were a
rising female incidence, a bimodal age distribution in women,
and an overall 20-year recurrence risk of 6.7%. Positive or uncertain
margins and younger age at diagnosis showed an increased overallTable 3
Multivariate analysis of factors possibly associated with recurrence.
Complete-case analysis
b-Coefficient
Resection margins
Negative Reference
Positive 1.53
Uncertain 1.41
Female 0.15
Agea 0.86
Location
Parotid gland Reference
Submandibular gland 1.02
Minor gland 1.44
Deep lobe of parotid gland 0.13
Imputed analysis
b-Estimate
Resection margins
Negative Reference
Positive 1.47
Uncertain 1.38
Female 0.07
Age 0.04
Location
Parotid gland Reference
Submandibular gland 0.34
Minor gland 0.86
Deep lobe of parotid gland 0.24
Abbreviations: OR odds ratio; SE standard error; CI confidence interval.
a b and OR for 1 interquartile range (25 years) of change.risk of recurrence, whereas primary tumor locations in minor sali-
vary glands showed lower recurrence.Incidence
Direct comparisons with previous research on SGPA incidence
are hard to make. In the past 50 years, crude incidence figures
between 1.5 and 7.2 per 100,000 person-years [1,2,4,14–17] (Addi-
tional Table C) have been reported. However, most authors had not
categorized tumors by anatomical site, and only one paper dis-
cussed national figures, which related solely to parotid SGPAs
and did not standardize for age [4].
Interestingly, SGPA ESR in 2012 was 4.7 per 100,000 person-
years, whereas salivary-gland cancer ESR in 2010 was 0.74 [24].
These figures indicate that any salivary gland lump is 6.5 times
more likely to be SGPA than carcinoma.
The 1% annual increase of SGPA ESR in women was a remark-
able finding, as was the female preponderance of SGPA. Possibly,
women are more aware of their appearance than men and more
willing to seek medical attention for any lumps they find [25–
27]. On the other hand, there may also be an influence of gonadal
hormones, as in breast cancer, since SGPA is known to express
estrogen and progesterone receptors [28,29]. Salivary gland neo-
plasms have been associated with breast cancer before [30]. One
risk factor for breast cancer is advanced maternal age at first child-
birth [31–33]. In the Netherlands, this age rose from 28.0 to 29.4 in
the period we investigated [18]. A link with the increase we found
in female SGPA incidence is not inconceivable.Patient, tumor, and treatment characteristics
The bimodal age distribution in female SGPA incidence remains
unexplained. Further research is needed to explore any hormone
influences.SE (of b) OR (95% CI) p-value
0.25 4.62 (2.84–7.51) <0.001
0.31 4.08 (2.24–7.43) <0.001
0.23 1.16 (0.75–1.81) 0.501
0.18 0.42 (0.29–0.63) <0.001
0.60 0.36 (0.11–1.16) 0.087
0.60 0.24 (0.07–0.77) 0.016
0.45 1.13 (0.47–2.73) 0.778
SE OR (95% CI) p-value
0.24 4.35 (2.75–6.96) <0.001
0.29 3.98 (2.23–7.10) <0.001
0.19 0.93 (0.63–1.35) 0.711
0.01 0.96 (0.95–0.97) <0.001
0.38 0.71 (0.34–1.51) 0.374
0.38 0.42 (0.20–0.89) 0.024
0.39 1.28 (0.59–2.75) 0.535
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otid, submandibular, and minor glands in a ratio of 10:1:1 [1,34].
The ratio we found was 12:1:2, possibly because of an absence of
selection bias in our data.
In our cohort, submandibular SGPAs were more common in
women than in men, whereas minor salivary gland SGPAs were
more common in men than in women. Since we found no previous
mention of any sex differences in SGPA location, further research is
needed to confirm and explain this finding.
As the PALGA database focuses on pathology, information on
the type of surgery performed was often missing (42%). Recently,
new insights about the benefits of standardized structured pathol-
ogy reporting [35] have led to improved reporting practices for
high-incidence cancers in Dutch laboratories. Hopefully, this sys-
tematic approach will be adopted for other diseases, too, including
for SGPA.
Resection margins had not been recorded in 21% of cases. In a
posthoc analysis, these cases turned out to have a 1.5-fold higher
likelihood of recurrence, even after adjustment for gender, age,
location and type of treatment. There may be several reasons
why margin data are often missing. First, SGPAs are usually
removed without complete margins of normal salivary gland tis-
sue, for instance when they are close to the facial nerve. Second,
covering (pseudo) capsules may be very thin, and multinodular
growth patterns make it hard to determine whether any nodules
have been left behind. Third, SGPAs are benign, so there is little pri-
ority in describing their margins, unless the pathology order holds
a specific request to do so, along with sufficient clinical
information.
Recurrence rates and malignant transformation
Whereas the 4.6% first-recurrence rate we found in patients
with at least five years of follow-up (n = 2719) replicates previous
findings [6], our 12% second-recurrence rate at five years is lower
than the 14% stated in most papers (Additional Table D). However,
some caution is needed here, as populations and follow-up periods
vary between cohorts, and none of the figures have taken any clin-
ical or mortality data into account.
For this present research project, we excluded malignant trans-
formations of primary SGPA, diagnosed as carcinoma ex pleomor-
phic adenoma at first presentation without a history of SGPA. In
earlier research, however, we found 34 cases of salivary gland car-
cinoma ex pleomorphic adenoma in the same period of investiga-
tion [24]. Four occurred in recurrent SGPA and were added to our
database, leaving 30 cases to account for a 1.1% risk of de novo
malignant transformation of primary SGPA (30 in 2749). This is a
similar percentage as the 1.7% that could be calculated from the
population in Denmark [4]. Earlier publications reported a mean
6.2% risk, but their figures relate to single-centre data and may
reflect a referral bias [10,36].
The 0.15% secondary malignant transformation rate we found
(carcinoma ex pleomorphic adenoma in recurrent SGPA in our
SGPA cohort; 3.2% of all recurrences) is in the lower range of earlier
findings [6]. These numbers are also lower than in Denmark,
reported at 0.35% and 12.6% respectively. To some extent, the dif-
ferences may be explained by different inclusion criteria, but more
importantly, compared to smaller studies, we ruled out referral
bias by compiling a nationwide cohort, rather than using single-
centre data.
Our results confirm that at a population level, complete surgical
removal of SGPA can be difficult, leading to a 4.6% first-recurrence
rate and a 16% second-recurrence rate (median times to recurrence
7 and 2 years, respectively). Recurrences are often multinodular,
with a mean number of 26 nodules (range 1–266) found in the pri-
mary resection bed [37]. These figures provide a strong argumentfor MRI follow-up after all first recurrences, to avoid a need for
more extensive surgery at some later point in time.
Risk factors for recurrence
We found margin status to be the primary risk factor for recur-
rence. However, our margin data were based on microscopy,
whereas in practice, margin status is often determined macroscop-
ically by the surgeon. In many resections, sufficient margins cannot
be taken because of adjacent facial nerve branches, and the pathol-
ogist will only have a very thin capsule to examine. This problem
may raise doubt as to the reliability of microscopy data for multi-
variate analysis. Still, if margins are positive or uncertain, it is
highly plausible to expect higher recurrence, since positive micro-
scopic margins are accepted as a primary cause for tumors to recur,
as are rupture and spillage [6,5].
A second recurrence risk factor we found was age. Mean age at
primary SGPA diagnosis was 49 in patients who did not develop a
recurrence later on, and 40 in patients who did. Although there
may be an age bias here (higher age suggesting shorter survival,
with death as a competing event), our findings are in line with lit-
erature [34,38–40]. Some researchers have explained the age dif-
ference by suggesting that surgeons tend to take a less radical
approach and make smaller incisions in younger patients, for
esthetic reasons [37]. Our multivariate analysis, however, did not
show any correlation between age and margin status. Wittekindt
et al. observed a further age difference. In their study population,
mean age at primary diagnosis turned out to be lower in single-
recurrence patients than in multiple-recurrence patients (30.2 ver-
sus 40.3) [37]. Possibly, tumor biology is somehow different in
younger patients, because of hormonal aspects, genetic back-
ground, or some other factor as yet unknown.
A third risk factor for recurrence in our cohort was tumor loca-
tion, which to our knowledge is a novel finding. SGPA in minor sali-
vary glands was found to recur less frequently than SGPA in larger
glands. Lumps in the minor glands are possibly more likely to be
noted at an earlier stage. Moreover, complete excision of these
lumps is easier to achieve, although margin status may be hard
to assess for lack of capsule formation [41].
Female gender was not found to be a recurrence risk factor,
which is in line with Maran et al. [42] in smaller series, but in con-
trast to other publications [37,43,44].
Limitations
There are some limitations to our study. First, there is a slight
information bias. Given the suboptimal diagnostic accuracy of
cytology (84–99%) [45], we included histology-confirmed SGPA,
only. With only 98 cytology diagnoses, however, and no data on
nonpathology-proven recurrences, the 4.6% recurrence rate we
found may be something of an underestimate, although hardly a
gross one.
A second limitation is the lack of radiotherapy data, because lit-
erature suggests there is a role for radiotherapy in the adjuvant
treatment of recurrent SGPA.
Third, since we retrieved all our information from nonstandard-
ized pathology reports, there may be an interpretation bias con-
cerning the description of margins by pathologists and the
information supplied by surgeons.Conclusion
Nationwide pathology data regarding SGPA in the Netherlands
in the period 1992–2012 reflect some remarkable incidence
trends: female incidence was on the rise, there was a bimodal
M.H. Valstar et al. / Oral Oncology 66 (2017) 93–99 99age distribution in women, and women were affected more often
than men. These findings may suggest some underlying hormonal
mechanism.
Overall figures for this period showed an ESR ranging between
4.2 and 4.9 per 100,000 person-years, a 4.6% first-recurrence rate
after at least five years of follow-up, and a 6.7% recurrence rate
at 20 years of follow-up. Malignant transformation had occurred
in 1.1% of primary, and 0.15% of secondary SGPAs at 5 years of
follow-up (3.2% of all recurrences).
Risk factors for recurrence were positive or uncertain surgical
margins, younger age at primary diagnosis, and primary tumor
location, with lower odds for minor-gland primaries to recur, when
compared to parotid SGPAs. Where margin data were missing, the
odds of recurrence were higher, which emphasizes the need for
improved, possibly standardized reporting in a joint effort by both
surgeons and pathologists alike.
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